Clinical trial

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of…

NCT00192153 · MedImmune LLC, Industry · Completed

Key facts

NCT number NCT00192153
Title Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older
Official title A Randomized, Partially-Blinded, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Adults 18 to 59 Years and Healthy Adults,60 Years/Older
Lead sponsor MedImmune LLC, Industry
Collaborators Wyeth is now a wholly owned subsidiary of Pfizer Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Influenza
Intervention type Biological
Interventions CAIV-T or TIV
Enrollment 240
Start date Jul 1, 2001
Completion Oct 1, 2001
First posted Sep 19, 2005
Last update posted Sep 13, 2021
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies